4 Payout Plays To Plough Your Cash Into: BT Group plc, GlaxoSmithKline plc, Carillion plc And Barratt Developments PLC

Royston Wild explains why dividend hunters should check out BT Group plc (LON: BT.A), GlaxoSmithKline plc (LON: GSK), Carillion plc (LON: CLLN) and Barratt Developments PLC (LON: BDEV).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at four payout powerhouses that would supercharge any stocks portfolio.

BT Group

On first look BT (LSE: BT-A) may not be the most appetising payout pick out there, the firm having lagged the average market yield for some time now. And this trend is expected to continue for the medium term at least — the City expects the London company to shell out a reward of 14.4p per share for the 12 months ending March 2016, yielding just 3.2% versus 3.4% for the wider FTSE 100.

Still, I believe that BT’s terrific long-term earnings prospects should keep the firm’s ultra-progressive dividend policy in business. Indeed, the firm has lifted the total payment at a blistering compound annual growth rate of 13.8% during the past five years as profits have rocketed higher. BT is anticipated to raise the payout to 15.7p in 2017, yielding 3.5%, and with a rising subscriber base driving the bottom line higher and cash flows also on the rise, I expect dividends to continue blasting skywards.

GlaxoSmithKline

The capital-intensive nature of GlaxoSmithKline’s (LSE: GSK) operations have cast some doubts over the scale of shareholder rewards in future years. To try and assuage these fears the pharma play has vowed to shell out a dividend of 80p per share right through to the close of 2017, a figure that creates an almost-unrivalled yield of 5.8%.

Of course there is no guarantee that GlaxoSmithKline will be able to make good on these promises, particularly as vast sums are required for the Brentford firm to develop new drugs and put to bed the enduring problem of patent losses. But I believe that GlaxoSmithKline’s pedigree in getting product from lab bench to market — its exciting mepolizumab anti-asthma drug received FDA approval for adults just last month — combined with further rounds of extensive cost-cutting should keep dividends trucking along at generous levels.

Carillion

I am convinced that construction giant Carillion’s (LSE: CLLN) ability to grind out contract win after contract win with major private- and public-sector customers should maintain steady dividend growth as the bottom line swells. Even though construction data remains patchy, on a longer-term time horizon I believe the fruits of an improving UK economy should continue sending business Carillion’s way.

Meanwhile, the building play’s ability to throw up massive amounts of cash should copper-bottom investor confidence in dividends looking ahead, in my opinion. This view is shared by the number crunchers, who expect the business to lift the dividend from 17.75p per share in 2015 to 18.2p in 2016, and again to 18.9p in the following year. Consequently Carillion carries vast yields of 5.2% and 5.4% for these periods.

Barratt Developments

Make no mistake: the colossal gap between housing supply and demand in Britain is not likely to be fixed anytime soon. Such a scenario is playing into the hands of homebuilders such as Barratt Developments (LSE: BDEV), and with interest rates set to remain low well into 2016 at the earliest; lending products becoming cheaper and cheaper for new buyers; and owners becoming increasingly reluctant to put their properties on the market, the imbalance is only likely to get worse.

With home prices likely to keep surging as a result, the earnings outlook at the likes of Barratt Developments is as strong as at any time in recent memory. Subsequently the company is predicted to transform last year’s 10.3p-per-share dividend to 22.9p in the year concluding June 2016, producing a chunky yield of 3.6%. And this readout leaps to 4.5% for 2017 amid expectations of a 28.6p payment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild owns shares of Barratt Developments. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Is Avon Protection the best stock to buy in the FTSE All-Share index right now?

Here’s a stock I’m holding for recovery and growth from the FTSE All-Share index. Can it be crowned as the…

Read more »

Investing Articles

Down 8.5% this month, is the Aviva share price too attractive to ignore?

It’s time to look into Aviva and the insurance sector while the share price is pulling back from year-to-date highs.

Read more »

Investing Articles

Here’s where I see Vodafone’s share price ending 2024

Valued at just twice its earnings, is the Vodafone share price a bargain or value trap? Our writer explores where…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

The Darktrace share price jumped 20% today. Here’s why!

After the Darktrace share price leapt by a fifth in early trading, our writer explains why -- and what it…

Read more »

Dividend Shares

850 shares in this dividend giant could make me £1.1k in passive income

Jon Smith flags up one dividend stock for passive income that has outperformed its sector over the course of the…

Read more »

Investing Articles

Unilever shares are flying! Time to buy at a 21% ‘discount’?

Unilever shares have been racing higher this week after a one-two punch of news from the company. Here’s whether I…

Read more »

artificial intelligence investing algorithms
Market Movers

The Microsoft share price surges after results. Is this the best AI stock to buy?

Jon Smith flags up the jump in the Microsoft share price after the latest results showed strong demand for AI…

Read more »

Google office headquarters
Investing Articles

A dividend announcement sends the Alphabet share price soaring. Here’s what investors need to know

As the Alphabet share price surges on the announcement of a dividend, Stephen Wright outlines what investors should really be…

Read more »